Psyence Biomedical Ltd. (PBM) Stock
PBM Key Statistics
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
CEO: Jody Aufrichtig. Company website
PBM — Frequently Asked Questions
What is the PBM stock price today?
Psyence Biomedical Ltd. (PBM) trades at $5.08, down 21.73% on the day, as of Sep 20, 2026 15:01 UTC.
What is Psyence Biomedical Ltd.'s market cap?
Psyence Biomedical Ltd. has a market capitalisation of $96,616.52, calculated from the live PBM share price and shares outstanding.
What is the P/E ratio of PBM?
PBM trades at a trailing P/E of 1.02, from earnings per share of $4.99 over the last twelve months.
How much revenue does Psyence Biomedical Ltd. make?
Psyence Biomedical Ltd. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for PBM?
PBM has traded between $2.26 and $16.96 over the past 52 weeks, and the last price is 70.0% below that high.
Is Psyence Biomedical Ltd. profitable?
Yes. Psyence Biomedical Ltd. keeps 0.00% of revenue as net income over the trailing twelve months.
What sector is Psyence Biomedical Ltd. in?
Psyence Biomedical Ltd. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in CA .
Who is the CEO of Psyence Biomedical Ltd.?
Jody Aufrichtig is the chief executive of Psyence Biomedical Ltd., which employs 12 people.
Where can I track PBM in real time?
QFI Terminal shows PBM with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See PBM live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PBM in Terminal See plans